

Provisional 2022 EphMRA ATC Developments

The following new class structures were voted on by EphMRA/PBIRG in May/June 2021 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2022 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2021. The new structures then come into effect from the beginning of 2022.

Antivirals

New class for antivirals against the coronavirus group, including COVID-19.

J5B6	Coronavirus antivirals
	Includes products containing bamlanivimab, casirivimab, etesevimab, favipiravir, imdevimab, remdesivir etc, for treatment of COVID-19.

Antineoplastics, protein kinase inhibitors

New class for hedgehog pathway inhibitors used as antineoplastics.

L1X6	Hedgehog pathway inhibitor antineoplastics
	Includes products containing glasdegib, sonidegib, vismodegib, etc.

Antineoplastics

In order to make more fourth level classes available for emerging classes of products in L1X (All other antineoplastics), two current fourth level classes in L1X will become third level classes.

L1X2	Lidomide antineoplastics	to	L1K	LIDOMIDE ANTINEOPLASTICS
L1X4	PARP inhibitor antineoplastics	to	L1L	PARP INHIBITOR ANTINEOPLASTICS